{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=39&sponsor=Janssen+Research+%26+Development%2C+LLC",
    "query": {
      "sponsor": "Janssen Research & Development, LLC",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 703,
    "total_pages": 71,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=40&sponsor=Janssen+Research+%26+Development%2C+LLC&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=38&sponsor=Janssen+Research+%26+Development%2C+LLC&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T14:28:53.533Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03145181",
      "title": "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Teclistamab (IV)",
          "type": "DRUG"
        },
        {
          "name": "Teclistamab(SC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2017-05-16",
      "completion_date": "2027-08-24",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Denver, Colorado • New York, New York + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03145181"
    },
    {
      "nct_id": "NCT06143878",
      "title": "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "JNJ-77242113",
          "type": "DRUG"
        },
        {
          "name": "JNJ-77242113 Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Deucravacitinib",
          "type": "DRUG"
        },
        {
          "name": "Deucravacitinib Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 774,
      "start_date": "2024-01-17",
      "completion_date": "2027-06-01",
      "has_results": true,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 50,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06143878"
    },
    {
      "nct_id": "NCT07746687",
      "title": "A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "JNJ-95597528",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 440,
      "start_date": "2026-10-05",
      "completion_date": "2030-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 7,
      "location_summary": "Westminster, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07746687"
    },
    {
      "nct_id": "NCT07871435",
      "title": "GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "GI-102",
          "type": "DRUG"
        },
        {
          "name": "Pasritamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GI Innovation, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 107,
      "start_date": "2026-10-12",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07871435"
    },
    {
      "nct_id": "NCT02993237",
      "title": "Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "DRV/COBI FDC placebo tablet",
          "type": "DRUG"
        },
        {
          "name": "D/C/F/TAF FDC placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-01-23",
      "completion_date": "2017-05-25",
      "has_results": false,
      "last_update_posted_date": "2019-05-13",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02993237"
    },
    {
      "nct_id": "NCT01106625",
      "title": "The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sulphonylruea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 469,
      "start_date": "2010-05",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 37,
      "location_summary": "Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106625"
    },
    {
      "nct_id": "NCT05357755",
      "title": "A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "JNJ-77242113",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2022-06-13",
      "completion_date": "2023-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05357755"
    },
    {
      "nct_id": "NCT03251482",
      "title": "A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery"
      ],
      "interventions": [
        {
          "name": "JNJ-64179375 0.3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 0.6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 1.2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 (Dose to be Determined)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 A mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 B mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 C mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 D mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo JNJ-64179375",
          "type": "DRUG"
        },
        {
          "name": "Apixaban placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban 2.5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 308,
      "start_date": "2017-11-13",
      "completion_date": "2018-11-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03251482"
    },
    {
      "nct_id": "NCT01032629",
      "title": "CANVAS - CANagliflozin cardioVascular Assessment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Cardiovascular Diseases",
        "Risk Factors"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin (JNJ-28431754) 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin (JNJ-28431754) 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 4330,
      "start_date": "2009-12-09",
      "completion_date": "2017-02-22",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01032629"
    },
    {
      "nct_id": "NCT01809327",
      "title": "A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1186,
      "start_date": "2013-06-04",
      "completion_date": "2014-12-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-11-05T14:28:53.533Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01809327"
    }
  ]
}